Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 21;11(9):2586.
doi: 10.3390/biomedicines11092586.

Clinical Approaches to Nestorone Subdermal Implant Therapy in Women's Health

Guilherme Renke  1   2 , Consuelo Callizo  3 , Raphaela Paes  1 , Mariana Antunes  1 , Glaycon Michels  1 , Luana Concha  1 , Ordânio Almeida  1 , Christiane Valente  1 , Thomaz Baesso  1 , Bruna Giovannoni  1
Affiliations
Review

Clinical Approaches to Nestorone Subdermal Implant Therapy in Women's Health

Guilherme Renke et al. Biomedicines. .

Abstract

Segesterone acetate (SA) or Nestorone, a fourth-generation progestogen, is a synthetic compound with high progestational activity and no androgenic, glucocorticoid, or anabolic effects. However, due to its oral inactivity, SA must be used by other routes, such as subcutaneous. Thus, considering its peculiar properties, the SA subdermal implant is successfully used in female contraception and postmenopausal hormone replacement therapy (HRT). In recent years, its potential uses in endometriosis, polycystic ovaries syndrome (PCOS), and a new therapeutic possibility for neuroprotection have made this treatment extremely interesting. However, the absence of a standardized dose and the long-term safety of SA implant therapy in women is still controversial. Here, we present the possible indications, doses, limitations, and side effects of SA implant therapy.

Keywords: Nestorone; contraception; hormone; hormone replacement therapy; implant; menopause; neuroprotection; segesterone acetate.

PubMed Disclaimer

Conflict of interest statement

C.C. is a research physician at ELMECO Hormonal Implants. All other authors declare that they have no competing interest.

Figures

Figure 1
Figure 1
Characteristics of synthetic progestin SA. (SA: segesterone acetate).
Figure 2
Figure 2
SA subdermal silastic implant.
Figure 3
Figure 3
SA activity and mechanisms of action. (SA: segesterone acetate; PR: progesterone receptor; P: progesterone; SHBG: sexual hormone binding globulin; AR: androgen receptor).
See this image and copyright information in PMC

References

    1. Ambacher K., Secter M. The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: A systematic review. Curr. Med. Res. Opin. 2022;38:479–486. doi: 10.1080/03007995.2022.2031144. - DOI - PubMed
    1. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47:277–283. doi: 10.1016/j.maturitas.2004.01.001. - DOI - PubMed
    1. Kumar N., Koide S.S. Nestorone: A progestin with a unique pharmacological profile. Steroids. 2000;65:629–636. doi: 10.1016/S0039-128X(00)00119-7. - DOI - PubMed
    1. Gemzell-Danielsson K., Sitruk-Ware R. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation. Contraception. 2019;99:323–328. doi: 10.1016/j.contraception.2019.02.001. - DOI - PMC - PubMed
    1. Weisberg E., Brache V. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethynil estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. Contraception. 2005;72:46–52. doi: 10.1016/j.contraception.2004.12.014. - DOI - PubMed

Grants and funding

LinkOut - more resources